This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Why Is Ecolab (ECL) Up 0.2% Since Last Earnings Report?
by Zacks Equity Research
Ecolab (ECL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Ecolab's (ECL) Certified Program to Build Customer Confidence
by Zacks Equity Research
Ecolab's (ECL) science-backed comprehensive program to help food retailers to support customer confidence.
Ecolab (ECL) Q4 Earnings In Line With Estimates, Revenues Lag
by Zacks Equity Research
Although Ecolab's (ECL) fourth-quarter results reflect weakness in the Global Industrial and Institutional segments, its Global Healthcare and Life Sciences unit shows strength.
Ecolab (ECL) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Ecolab's (ECL) fourth-quarter results are likely to reflect gains from the Global Healthcare and Life Sciences segment.
Earnings Preview: Ecolab (ECL) Q4 Earnings Expected to Decline
by Zacks Equity Research
Ecolab (ECL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Quidel (QDEL) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Quidel (QDEL) is likely to have witnessed a recovery in rapid immunoassay revenues during Q4.
DuPont (DD) Warms Up to Q4 Earnings: What's in the Offing?
by Zacks Equity Research
DuPont (DD) is likely to have benefited from its cost and productivity actions in the fourth quarter.
Cardinal Health (CAH) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
Cardinal Health's (CAH) fiscal second-quarter results are likely to reflect solid performance in Pharmaceutical segment.
What's in Store for Meridian Bioscience's (VIVO) Q1 Earnings?
by Zacks Equity Research
Meridian Bioscience's (VIVO) fiscal first-quarter results are likely to reflect strong performance by Life Science business line.
Air Products (APD) to Post Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Benefits of productivity and pricing actions, new plants and acquisitions are expected to get reflected on Air Products' (APD) Q1 results.
CE vs. ECL: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
CE vs. ECL: Which Stock Is the Better Value Option?
AmerisourceBergen (ABC) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
AmerisourceBergen's (ABC) fiscal first-quarter results are likely to reflect solid performance at Pharmaceutical Distribution and Other units.
Baxter (BAX) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Baxter's (BAX) fourth-quarter performance is likely to reflect growth in its Acute Therapies business.
What's in Store for Material ETFs in Q4 Earnings?
by Sweta Killa
Let's delve into the earnings picture of the companies that would drive the performance of materials ETFs as these dominate their portfolio.
PerkinElmer (PKI) to Post Q4 Earnings: What's in the Cards?
by Zacks Equity Research
PerkinElmer's (PKI) fourth-quarter results are likely to reflect strong performance at Diagnostics segment.
McKesson (MCK) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
McKesson's (MCK) fiscal third-quarter results are likely to reflect solid show by U.S. Pharmaceutical and Specialty Solutions segment.
LyondellBasell (LYB) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
LyondellBasell's (LYB) Q4 performance is likely to have benefited from higher demand for polyethylene.
ABIOMED (ABMD) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
The strong momentum of ABIOMED's (ABMD) Impella product line, both in Europe and Japan, is expected to have continued in the fiscal third quarter as well.
BD (BDX) Gears Up for Q1 Earnings: What's in the Offing?
by Zacks Equity Research
BD's (BDX) first-quarter fiscal 2021 results are likely to reflect strong year-over-year growth in revenues from assays in its Life Sciences segment.
Stryker (SYK) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Stryker's (SYK) fourth-quarter results are likely to reflect strong segmental performances at Medsurg, Orthopaedic and Neurotechnology & Spine.
Celanese (CE) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Celanese's (CE) Q4 performance is likely to have benefited from productivity actions, investments in high-return organic projects and strategic acquisitions.
Varian (VAR) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Varian's (VAR) fiscal first-quarter earnings are likely to reflect strength in Halcyon platform.
Freeport (FCX) to Post Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Freeport's (FCX) fourth-quarter results are likely to reflect the benefits of higher copper prices.
PPG Industries (PPG) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
PPG Industries' (PPG) performance is likely to have benefited from cost-cutting and restructuring actions in Q4.
CE vs. ECL: Which Stock Is the Better Value Option?
by Zacks Equity Research
CE vs. ECL: Which Stock Is the Better Value Option?